Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' Fourth Quarter and Full Year 2023 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (FENC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Southpoint Capital Advisors John Smith Clark | 4,077,214 | $45,746,341 | 0.98% | |
| 2. | Solas Capital Management Frederick Tucker Golden | 1,378,513 | $15,466,916 | -21% | 9.6% |
| 3. | VenBio Select Advisor Kurt Von Emster | 1,200,000 | $13,464,000 | 0.18% | |
| 4. | DG Capital Management Dov Gertzulin | 1,075,634 | $12,068,613 | -6% | 7.45% |
| 5. | Harbert Management Raymond J. Harbert | 466,869 | $5,238,270 | 3.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 12,500 | 104,271 | 2024-04-01 | Filing | ||
| $0.00 | 29,167 | 316,638 | 2024-04-01 | Filing | ||
| $6.25 | 80,000 | Large Shareholder | 4,077,214 | 2020-05-04 | Filing | |
| $6.25 | 768,000 | Large Shareholder | 3,993,694 | 2020-04-30 | Filing | |
| $10.23 | 2,000 | Large Shareholder | 1,674,614 | 2017-10-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.45 | 800 | 44,449 | 2024-04-15 | Filing | ||
| $10.75 | 44,300 | 187,471 | 2024-04-05 | Filing | ||
| $10.89 | 29,700 | 231,771 | 2024-04-04 | Filing | ||
| $10.89 | 14,583 | 261,471 | 2024-04-04 | Filing | ||
| $10.78 | 26,000 | 276,054 | 2024-04-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,407,357 | $27,010,546 | 31.02% | |
| 2. | 1,140,063 | $12,791,507 | 0% | |
| 3. | 934,591 | $10,486,110 | 0% | |
| 4. | 265,650 | $2,980,593 | 0% | |
| 5. | 218,590 | $2,452,579 | 0% |
News See All
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2023 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to the Fennec Pharmaceuticals Second Quarter 2023 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals First Quarter 2023 Earnings and Corporate Update Conference Call.
Top 5 Stock Picks of Lawrence Kam's Sonic Capital
In this article, we will take a look at the top 5 stock picks of Lawrence Kam's Sonic Capital.
Hedge Funds Are Piling Into Fennec Pharmaceuticals Inc. (FENC)
In this article you are going to find out whether hedge funds think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a good investment right now.
Here is What Hedge Funds Think About Fennec Pharmaceuticals Inc. (FENC)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Hedge Funds Souring On Fennec Pharmaceuticals Inc. (FENC)
In this article you are going to find out whether hedge funds think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a good investment right now.
Is Fennec Pharmaceuticals Inc. (FENC) A Good Stock To Buy?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
AxoGen and Blueprint Medicines Help Opaleye Return 91% Over the Last Year
James A. Silverman founded Opaleye Management back in 1996 and it was formerly known as Risk/Reward Capital.